Viart N, Renault A, Eon-Marchais S, Jiao Y, Fuhrmann L, El Houdigui S
Breast Cancer Res. 2025; 27(1):36.
PMID: 40069712
PMC: 11899765.
DOI: 10.1186/s13058-025-01988-w.
Blanco R, Munoz J
Biology (Basel). 2025; 14(2).
PMID: 40001942
PMC: 11851556.
DOI: 10.3390/biology14020174.
Sweatman E, Bayley R, Selemane R, Higgs M
Br J Cancer. 2025; .
PMID: 39994444
DOI: 10.1038/s41416-025-02963-0.
Guadagnolo D, Minucci A, Chiavassa A, Gentile G, Salvatori F, Khaleghi Hashemian N
Mol Biol Rep. 2025; 52(1):261.
PMID: 39984762
PMC: 11845405.
DOI: 10.1007/s11033-025-10357-x.
Ho J, Cheng E, Wong C, St-Germain J, Dunham W, Raught B
EMBO Rep. 2025; 26(5):1290-1314.
PMID: 39870965
PMC: 11894219.
DOI: 10.1038/s44319-025-00374-z.
Adjusting for Ascertainment Bias in Meta-Analysis of Penetrance for Cancer Risk.
Ruberu T, Braun D, Parmigiani G, Biswas S
Stat Med. 2025; 44(3-4):e10323.
PMID: 39865362
PMC: 11881752.
DOI: 10.1002/sim.10323.
Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity.
Nuijens A, Oei A, Franken N, Rasch C, Stalpers L
Curr Oncol. 2025; 32(1).
PMID: 39851963
PMC: 11763857.
DOI: 10.3390/curroncol32010047.
Breast Cancer Susceptibility Gene Sequence Variations and Development of Contralateral Breast Cancer.
Reiner A, Watt G, Malone K, Lynch C, John E, Knight J
JAMA Netw Open. 2025; 7(12):e2452158.
PMID: 39786405
PMC: 11686411.
DOI: 10.1001/jamanetworkopen.2024.52158.
Swedish Genome-Wide Haplotype Association Analysis Suggests Breast Cancer Loci with Varying Risk-Modifying Effects.
Vermani L, Barnekow E, Liu W, Wendt C, Hall P, Margolin S
Genes (Basel). 2025; 15(12.
PMID: 39766883
PMC: 11675172.
DOI: 10.3390/genes15121616.
High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia.
Shumilova S, Danishevich A, Nikolaev S, Krasnov G, Ikonnikova A, Isaeva D
Int J Mol Sci. 2024; 25(23).
PMID: 39684352
PMC: 11641773.
DOI: 10.3390/ijms252312640.
Germline Variant Spectrum in Southern Italian High-Risk Hereditary Breast Cancer Patients: Insights from Multi-Gene Panel Testing.
Rocca V, Lo Feudo E, Dinatolo F, Lavano S, Bilotta A, Amato R
Curr Issues Mol Biol. 2024; 46(11):13003-13020.
PMID: 39590369
PMC: 11592649.
DOI: 10.3390/cimb46110775.
Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer.
Hayashi T, Sano K, Okada M, Muto M, Konishi I
Curr Oncol. 2024; 31(11):6723-6734.
PMID: 39590127
PMC: 11592444.
DOI: 10.3390/curroncol31110496.
Gene-based burden tests of rare germline variants identify six cancer susceptibility genes.
Ivarsdottir E, Gudmundsson J, Tragante V, Sveinbjornsson G, Kristmundsdottir S, Stacey S
Nat Genet. 2024; 56(11):2422-2433.
PMID: 39472694
DOI: 10.1038/s41588-024-01966-6.
Implementing the Risk Stratification and Clinical Management of Breast Cancer Families Using Polygenic Risk Score Evaluation: A Pilot Study.
Rizzacasa B, Nicoli V, Tancredi C, Conte C, Salehi L, Carriero M
J Pers Med. 2024; 14(10).
PMID: 39452541
PMC: 11508219.
DOI: 10.3390/jpm14101034.
Germline BRCA1-Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long-Term Survival.
Kubo T, Ikeda Y, Muramatu J, Ishikawa K, Yoshida M, Kukita K
Cancer Rep (Hoboken). 2024; 7(8):e70007.
PMID: 39188100
PMC: 11347749.
DOI: 10.1002/cnr2.70007.
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
Lee J, Kida K, Koh J, Liu H, Manyam G, Gi Y
J Exp Clin Cancer Res. 2024; 43(1):236.
PMID: 39164784
PMC: 11337831.
DOI: 10.1186/s13046-024-03143-3.
Male Breast Cancer: Current Scenario and Future Perspectives.
Chidambaram A, Prabhakaran R, Sivasamy S, Kanagasabai T, Thekkumalai M, Singh A
Technol Cancer Res Treat. 2024; 23:15330338241261836.
PMID: 39043043
PMC: 11271170.
DOI: 10.1177/15330338241261836.
Genetic Testing of Breast Cancer Patients with Very Early-Onset Breast Cancer (≤30 Years) Yields a High Rate of Germline Pathogenic Variants, Mainly in the BRCA1, TP53, and BRCA2 Genes.
Apostolou P, Dellatola V, Papathanasiou A, Kalfakakou D, Fountzilas E, Tryfonopoulos D
Cancers (Basel). 2024; 16(13).
PMID: 39001430
PMC: 11240773.
DOI: 10.3390/cancers16132368.
Case-Case Genome-Wide Analyses Identify Subtype-Informative Variants That Confer Risk for Breast Cancer.
Sun X, Verma S, Jia G, Wang X, Ping J, Guo X
Cancer Res. 2024; 84(15):2533-2548.
PMID: 38832928
PMC: 11293972.
DOI: 10.1158/0008-5472.CAN-23-3854.
Bayesian meta-analysis of penetrance for cancer risk.
Ruberu T, Braun D, Parmigiani G, Biswas S
Biometrics. 2024; 80(2).
PMID: 38819308
PMC: 11140851.
DOI: 10.1093/biomtc/ujae038.